Dr. Dan Zhang has more than 10 year of drug development experience. He is the Chief Executive Officer of Fountain Medical Development, a full-service clinical CRO with primary operation in China. Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc, a US research arm of Sigma-Tau S.P.A., one of the largest Italy-based pharmaceutical firms with employees of 2300. Dr. Zhang managed the firm’s entire clinical development program in North American market, including oncology, cardiovascular, CNS, and metabolic development projects, in addition to his global role of drug safety handling.

Prior to his life at Sigma-Tau, Dr. Dan Zhang was a vice president at the Quintiles Transnational Corp.-the largest contract research organization (CRO) in the world, responsible for the planning and implementation of business development strategies in Greater China Area. He was also a member of Executive Operating Committee of Quintiles Transnational Corp. Dr. Zhang was also the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd., a whollyowned subsidiary of Quintiles Transnational Corp.

Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., and CIGNA Health Care, etc. His consulting services included clinical trial design, health economic studies, pricing and market-entry strategy.

Over last ten years, Dr. Zhang established a strong working relationship with government and academic institutions in China. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. He was also a visiting professor at the Harbin Medical University of China. In addition, Dr. Zhang was a Ph.D. advisor and consultant for then Shanghai Medical University in the field of Pharmacoeconomic study and clinical trials. He is currently a senior consultant to Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-

American Professional Pharmaceutical Society (SAPA). He was the President (2006~2007), Chinese Biopharmaceutical Association-USA (CBA).

Dr. Zhang received his pre-med training from Beijing University and received his M.D. from Peking Union Medical College. He continued his study at the Harvard School of Public Health and received an MPH in health policy and management. Then he continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his master's degree in healthcare management in 1998 and is working on his Ph.D. dissertation in the field of health economics and finance.

Dr. Zhang has published several papers in the fields of medical research and health economics, and is a frequent speaker at various health care-related conferences.